Extended-release IPX-203 Reduces ‘Off’ Time in Advanced Parkinson’s

Extended-release IPX-203 Reduces ‘Off’ Time in Advanced Parkinson’s

304391

Extended-release IPX-203 Reduces ‘Off’ Time in Advanced Parkinson’s

Top-line data from a Phase 3 clinical trial testing IPX-203 showed Amneal Pharmaceuticals’ carbidopa-levodopa (CD/LD) extended-release capsules work better than immediate-release tablets at reducing “off” time in people with advanced Parkinson’s disease and motor fluctuations. These benefits were observed even when IPX-203 was taken two times less per day, on average, than immediate-release CD/LD tablets, taken five times a day. Based on these positive results, along with other supportive findings, Amneal announced its plans to…

You must be logged in to read/download the full post.